OTCMKTS:DTCFF Defence Therapeutics (DTCFF) Stock Price, News & Analysis $0.28 -0.01 (-2.68%) As of 10/12/2026 10:59 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Defence Therapeutics Stock (OTCMKTS:DTCFF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Defence Therapeutics alerts:Sign Up Key Stats Today's Range$0.28▼$0.2950-Day Range$0.27▼$0.4252-Week Range$0.25▼$0.78Volume3,000 shsAverage Volume8,220 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Defence Therapeutics Inc. is a Canadian biotechnology company focused on developing drug-delivery technologies and therapeutic candidates for cancer and other serious diseases. Its work centers on the Accum platform, which is designed to improve the delivery of biologic medicines into cells and enhance the effectiveness of treatments such as vaccines, antibody-drug conjugates and immunotherapies. The company’s development programs include AccuTOX, an oncology candidate intended to support targeted cancer treatment and immune activation, as well as AccuVAC vaccine applications designed to improve the delivery and performance of antigen-based vaccines. Defence Therapeutics has also investigated the use of its platform with antibody-drug conjugates and other biologic products. Defence Therapeutics was established in Canada and conducts research and development through collaborations and laboratory activities in North America. The company is led by President and Chief Executive Officer Sébastien Plouffe. Its programs remain focused on preclinical and clinical development, and the availability and status of individual candidates may change as research progresses.AI Generated. May Contain Errors. Read More Receive DTCFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DTCFF Stock News HeadlinesDefence Therapeutics Inc. (OTCMKTS:DTCFF) Stock Short Interest Jumps 271.3%October 11 at 2:40 PM | americanbankingnews.comDefence Therapeutics (OTCMKTS:DTCFF) Shares Climb 13.5% - Here's WhyOctober 6, 2026 | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 13 at 1:00 AM | The Oxford Club (Ad)Defence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug ConjugatesOctober 1, 2026 | finanznachrichten.deDefence Therapeutics Inc.: Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of DirectorsSeptember 29, 2026 | finanznachrichten.deDefence Therapeutics nomina Sherry Aulin nel consiglio di amministrazioneSeptember 29, 2026 | it.investing.comDefence Therapeutics : Provides Updates on Sharing AgreementSeptember 29, 2026 | marketscreener.comMDefence Therapeutics Inc.: Defence Therapeutics Provides Corporate Update as Company Executes on Strategic PrioritiesSeptember 28, 2026 | finanznachrichten.deSee More Headlines DTCFF Stock Analysis - Frequently Asked Questions How have DTCFF shares performed this year? Defence Therapeutics' stock was trading at $0.5576 at the beginning of 2026. Since then, DTCFF shares have decreased by 50.5% and is now trading at $0.2760. How do I buy shares of Defence Therapeutics? Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:DTCFF CIKN/A Webdefencetherapeutics.com Phone514 947 2272FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:DTCFF) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Defence Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
